Skip to main content
. Author manuscript; available in PMC: 2017 May 31.
Published in final edited form as: Int J Tuberc Lung Dis. 2013 Dec;17(12):1531–1537. doi: 10.5588/ijtld.13.0423

Table A.1.

Tuberculosis case rates and doses taken for patients participating in a clinical trial comparing 3HP with 9H;1 the follow-up period was 33 months

Cases py follow-up Cases per 100 py follow-up
9H
 0–90 doses 5 1377 0.36
 91–240 doses 4 1413 0.28
 241+ doses 6 7134 0.08
3HP
 0–8 doses 2 1503 0.13
 9+ doses 5 9116 0.05

3HP = 12-dose regimen of weekly rifapentine plus isoniazid; 9H = 9 months of daily, self-administered isoniazid; py = person-years.